31 killed by Israeli gunfire near aid center in S Gaza
Gaza, June 1 (UNI) At least 31 Palestinians were killed on Sunday by Israeli gunfire near a humanitarian aid center in southern Gaza.
At least 31 people were killed and dozens of others seriously injured in the morning when Israeli forces opened fire near a humanitarian aid distribution point in Rafah, southern Gaza, where residents were gathering to receive aid, Gaza-based health authority said in a statement.
Most of the injuries were in the upper body, and the death toll could rise due to the severity of the wounds, said Mohammed Abu Afash, director of the Medical Relief Organization in Gaza, adding that ambulances have difficulty reaching the scene due to ongoing Israeli military activities.
Eyewitnesses told media that thousands of people had arrived at the aid center since early morning hours when gunfire and explosions erupted.
Calling the incident part of a "pattern of repeated targeting" of aid distribution locations by Israel, the Hamas-run Gaza government media office said in a press statement that the area was operating in coordination with an American-Israeli company and under the supervision of Israeli forces.
Also on Sunday, the Israel Defense Forces said in a statement that it is unaware of injuries caused by its fire within the Humanitarian Aid distribution site, and that the matter is still under review.
Israeli media cited military sources as saying that Israeli military operations in the area were aimed at targeting "terrorist elements."
Israel closed border crossings and curtailed the flow of humanitarian aid into Gaza on March 2. Limited access has been permitted since May 22.
Israel resumed its assault on Gaza on March 18, following a two-month truce with Hamas. Since then, 4,149 Palestinians have been killed and 12,149 injured, according to Gaza-based health authorities on Sunday.
UNI XC GNK
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
37 minutes ago
- Time of India
Can oxygen therapy cheat aging? Bryan Johnson makes 'bizarre' claim after 90-day experiment
Bryan Johnson is not ready to desert his 'immortal' dream and his quest to 'live forever'! The American entrepreneur, venture capitalist, who has become widely known as a biohacker, has recently claimed that a 90-day regimen of hyperbaric oxygen therapy (HBOT) has significantly reversed his biological age, giving him the "biology of a 10-year-old. " This assertion is part of Johnson's broader quest to halt or even reverse aging, a mission he pursues through his venture, Blueprint. The experiment involved daily sessions in a pressurized chamber, breathing 95-100% pure oxygen, aiming to enhance tissue repair and rejuvenation. What is Hyperbaric Oxygen Therapy (HBOT)? HBOT is a medical treatment where individuals breathe pure oxygen in a pressurized chamber. This process increases oxygen levels in the blood, promoting faster healing and reducing inflammation. Under hyperbaric conditions, oxygen dissolves directly into plasma, allowing it to reach deeper tissues and areas with poor circulation. Each session typically lasts 60–120 minutes, depending on the condition being treated. But is HBOT all about benefits? Turns out, it's not. What are the potential side effects of this therapy? Hyperbaric Oxygen Therapy (HBOT) can have several potential side effects, ranging from mild to serious. Most complications are mild and temporary, but the risk of complications increases with longer and repeated therapies. Common side effects include ear pain, sinus pressure, and temporary vision changes. More serious complications, though rare, include lung damage, seizures, and low blood sugar. Who is Bryan Johnson? The Silicon Valley entrepreneur turned biohacker, Johnson, has garnered significant attention for his radical approach to anti-aging, known as "Project Blueprint." This initiative involves a stringent regimen of lifestyle modifications, including a strict diet, exercise routine, and the use of various medical treatments. He has invested approximately $2 million annually into this project, aiming to reverse his biological age and achieve optimal health. Johnson's anti-aging regimen: Johnson's daily routine is meticulously structured to optimize his physical and mental performance. He begins his day early, consuming a specialized supplement regimen and engaging in various health practices. His diet is plant-based, avoiding sugar and processed foods, and he adheres to strict sleep and exercise protocols. He also utilizes advanced therapies like stem cell injections and HBOT to maintain his body in a youthful state. Social media reactions to Johnson's methods: Johnson's methods have been met with both intrigue and skepticism. His previous experiments, such as blood transfusions from his teenage son, have drawn criticism from medical professionals and ethicists. These practices raise questions about consent, safety, and the potential implications of such interventions. While some consider his efforts groundbreaking, others question the scientific validity and ethical implications of his approach. For example, experts acknowledge that HBOT can aid in healing and tissue repair, but its long-term effects on aging are not well-established. Some researchers express skepticism about the extent of age reversal that Johnson claims, emphasizing the need for rigorous, peer-reviewed studies. Singer Arijit Singh's mother passes away due to COVID-19 complications One step to a healthier you—join Times Health+ Yoga and feel the change
Mint
40 minutes ago
- Mint
Stocks to watch: Yes Bank, Vodafone Idea, ITC, Adani Group, Grasim Industries among shares in focus today
Yes Bank shares will remain in focus once again today as its board is scheduled to meet to discuss a potential fundraising plan. Vodafone Idea (VIL) stated that it is in discussions with the central government to resolve the AGR matter, with CEO Akshaya Moondra expressing confidence that there is no justification for the government to be restricted in providing relief. Biocon has been granted approval to market the diabetes medication Liraglutide in India. Jindal Stainless announced that it has acquired a 33.64% equity stake in a special purpose vehicle (SPV) formed to build a 282 MW hybrid renewable energy project aimed at powering its manufacturing facilities. On May 28, US-based investment firm GQG Partners boosted its holdings in ITC Ltd, a leading Indian consumer goods company, by executing a bulk deal. HCL Tech revealed a strategic alliance with UiPath aimed at fast-tracking Agentic Automation for businesses worldwide. True North, a private equity firm, along with Niva Bupa Health Insurance CEO Krishnan Ramachandran, sold a total of 10 percent stake in the health insurance company for ₹ 1,507 crore via open market deals. The Adani Group is once again being investigated by the U.S. Department of Justice, according to the Wall Street Journal (WSJ), this time over allegations of importing Iranian liquefied petroleum gas (LPG) into India via the Mundra port. Aditya Birla Group's main holding company revealed that its Finance Committee has given the green light to issue non-convertible debentures (NCDs) totaling up to ₹ 1,000 crore. An Ahmedabad-based firm announced that it has entered into a long-term Sales and Purchase Agreement (SPA) with BP Singapore Pte Ltd, a subsidiary of the global energy giant BP, to supply up to 0.41 million tonnes per annum (MTPA) of liquefied natural gas (LNG) between 2027 and 2036. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Time of India
6 hours ago
- Time of India
Doctors develop new light-based treatment for rare eye infection
Hyderabad: Doctors at the LV Prasad Eye Institute in Hyderabad have discovered a new way to treat a rare but serious eye infection called acanthamoeba keratitis (AK) — a rare but serious eye infection that causes pain, redness, and can lead to vision loss. Tired of too many ads? go ad free now This infection is caused by amoeba found in places like water and soil. According to the study, it mostly affects people who wear contact lenses or come into contact with dirty water, such as those working on farms or using tap water to clean their lenses. Doctors tested a new light-based treatment called photodynamic therapy (PDAT-RB) and found it promising. The antimicrobial treatment uses a special dye called rose bengal, which is activated by light to produce powerful molecules that kill the infection. This, in turn, helped reduce inflammation in the eye. Rose bengal is a reddish-pink dye used in the diagnosis of eye conditions, which turned out to act as an effective photosensitising agent. Published in the United Kingdom-based Journal of Ophthalmic Inflammation and Infection, the study states that the most common cause of this disease is exposure of the eyes to contaminated water, especially in agricultural fields or washing contact lenses with tap water. An estimated 30-40% of patients suffering from AK require corneal transplantation, known as keratoplasty, on average. Despite that, many do not regain good visual acuity and require additional surgery. This study included 14 patients with AK infection. At first, they were given regular medicines to treat the infection. Then they received the new light-based PDAT treatment twice a week. The doctors used a solution with 0.1% rose bengal dye as part of the therapy. Tired of too many ads? go ad free now Doctors found that the treatment with the PDAT-RB reduced the need for corneal transplantation in 72% of the total patients with bacterial keratitis (inflammation of the cornea). Moreover, the infection was cleared in about 86% of patients within two to five months after the treatment. While most patients were suffering from almost complete vision loss before the treatment, only two of the total patients in the study required a corneal transplant to repair the damaged part. Although their vision improved after PDAT-RB therapy, they still had poor sight. On average, their vision went from total blindness to being able to see large objects or movement. Dr Gowtham Lakshminarayan, a research assistant scientist involved in the study, explained that the treatment works by creating powerful chemicals that destroy the harmful organisms in the eye. "The study suggests that if this treatment is used early, it can be a helpful and less-invasive (non-surgical) option to manage a severe eye infection that is usually hard to treat with regular medicines. The new treatment also shows that rose bengal is an effective photosensitiser and that early intervention with PDAT-RB treatment can yield promising results in the AK eye infection," he added.
